Samsung Biologics Completes GSK MD Facility Deal Samsung Biologics closed the acquisition of GSK's Maryland biologics facility on Mar 31, 2026, expanding its U.S. footprint and changing CDMO competitive dynamics.

Samsung Biologics Completes GSK MD Facility Deal: Samsung Biologics closed the acquisition of GSK's Maryland biologics facility on Mar 31, 2026, expanding its U.S. footprint and changing CDMO competitive dynamics. 👈 Read full analysis #SamsungBiologics #GSK #Biologics #CDMO #Pharmaceuticals

#trends today for 'training replacement' 'iran talks' & 'samsung biologics'

Click/Tap below:

www.newsmason.com?query=%22tra...

www.newsmason.com?query=%22ira...

www.newsmason.com?query=%22sam...

#trainingreplacement #irantalks #samsungbiologics

HLB, Can a Former Samsung Biologics CEO Deliver FDA Approval? HLB has embarked on a sweeping management overhaul as it prepares to reattempt U.S. Food and Drug Administration (FDA) approval for its liver cancer drug rivoc

HLB has embarked on a sweeping management overhaul as it prepares to reattempt U.S. Food and Drug Administration (FDA) approval for its liver cancer drug rivoceranib.
#HLB #FDA #rivoceranib #liver #cancer #SamsungBiologics #itchosun #chosun #SouthKorea #Korea #NewsUpdate

Samsung Biologics secures U.S. manufacturing base to enhance resilience of global biologics supply chain A landmark expansion: Samsung Biologics secures U.S. manufacturing base to enhance resilience of global biologics supply chain ROCKVILLE/SEOUL — In a major strategic development for the international biopharmaceutical sector, Samsung Biologics has signed a definitive agreement to acquire Human Genome Sciences from GSK — a move that instantly grants the South Korean giant its first […]

Samsung Biologics secures U.S. manufacturing base to enhance resilience of global biologics supply chain #SamsungBiologics #Biopharmaceuticals #GlobalSupplyChain #Biotech #Manufacturing

Samsung Biologics secures largest-ever deal with European pharma giant Samsung Group biotech unit is now Kospi's fourth-biggest company, outpacing world's largest CDMO, Lonza, in market cap Samsung Biologics has kicked off the start of 2025 with the largest single contra...

Samsung Group biotech unit is now Kospi's fourth-biggest company, outpacing world's largest CDMO, Lonza, in market cap

www.koreaherald.com/article/1039...

#SamsungBiologics

Samsung Biologics inks 2 new deals worth $668 mn with European pharma - Yes Punjab News Samsung Biologics secures two major contract manufacturing deals worth 930.4 billion won, surpassing 5 trillion won in total deals for 2023, marking a significant growth milestone.

Samsung Biologics inks 2 new deals worth $668 mn with European pharma
yespunjab.com?p=63123

#SamsungBiologics #ContractManufacturing #Biopharmaceutical #BiotechPartnerships #Europe